ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Developing medicines
  • Building a thriving environment for medicine discovery
  • How do we monitor and regulate medicines?
  • Sustainability

Sustainability

This tool was developed for the ABPI by the Carbon Trust with contributions from the ABPI, AstraZeneca, GlaxoSmithKline, Janssen (J&J), Eli Lilly, and Pfizer.

ABPI blister pack carbon footprint tool

The aim of the tool is to provide a quick approximation of the carbon impacts of pharmaceutical tablets in blister packs. This information can be used in assisting internal evaluations, assessing the carbon hot spots for individual products and screening product portfolios to prioritise more detailed footprinting studies and carbon reduction initiatives. In addition, it can be used to engage stakeholders in broader discussions around the carbon footprint impacts of products. The tool is specific to the UK pharmaceutical market.

You will need to acknowledge that you have read the terms and conditions before you can download the ABPI Blister Pack Carbon Footprint Tool.

  1. You may use and reproduce the tool for the purposes of your company’s internal business and may disclose the results of the tool to your employees, professional advisers and contractors for the purposes of implementing any of the recommendations set out in the tool in relation to energy saving and/or carbon reducing measures.

    For the avoidance of doubt, internal business means for your company’s own internal business or the internal business of any of your group or subsidiary companies. It does not extend to commercial exploitation.
     
  2. This tool was developed for the ABPI by the Carbon Trust with contributions from ABPI members.

    The aim of the tool is to provide a quick approximation of the carbon impacts of pharmaceutical tablets in blister packs. This information can be used in assisting internal evaluations, assessing the carbon hot spots for individual products and screening product portfolios to prioritise more detailed footprinting studies and carbon reduction initiatives. In addition, it can be used to engage stakeholders in broader discussions around the carbon footprint impacts of products. The tool is specific to the UK pharmaceutical market.

    Due to the variability in the quality of input data, the tool has inherent limitations as to the precision of results derived and all results will be quoted within ranges which the calculations will identify and display.

    In light of this, it must be recognised that the tool is not intended for, and should not be used as the basis of, direct product comparisons. In no circumstances can the ABPI or the Carbon Trust accept responsibility for any errors or omissions in the tool and to the fullest extent possible by English law, the ABPI and the Carbon Trust accept no liability for any losses users may suffer as a result of using the tool.

 

carbon_blister_pack.xlsm

How do we monitor and regulate medicines?

  • Sustainability
  • Drug safety (pharmacovigilance)

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.